Processa Pharmaceuticals, Inc. Proceeds from Notes Payable
Processa Pharmaceuticals, Inc. (PCSA) reported Proceeds from Notes Payable of $162.46 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2022-03-30
- Processa Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2020-12-31 was $0.00.
- Processa Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2020-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. proceeds from notes payable for the quarter ending 2013-09-30 was $9.91K.
- Processa Pharmaceuticals, Inc. proceeds from notes payable for fiscal 2020 was $162.46K.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month | Proceeds from Notes Payable 27 month | Proceeds from Notes Payable 30 month |
|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $0.00 derived: sum of 2 quarters · filed 2022-03-30 | $162.46K 10-K · filed 2022-03-30 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $162.46K 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $162.46K 10-Q · filed 2021-08-12 | |||||
| 2013-09-30 | $9.91K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-08 | $1.00M 10-Q · filed 2013-11-08 | $2.50M 10-Q · filed 2013-11-08 | |||
| 2013-06-30 | $990.09K 10-Q/A · filed 2013-09-06 | $2.49M 10-Q/A · filed 2013-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |